Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company, has named Kurt Gustafson as its new vice president of finance. Mr Gustafson will assume the role of CFO, effective May 15, 2009.
Subscribe to our email newsletter
David Ramsay, Halozyme’s current CFO, will transition to the new position of vice president of corporate development. Mr Ramsay joined Halozyme as CFO in 2003.
Mr Gustafson brings to Halozyme’s senior management team a unique combination of operational and managerial experience in financial planning and analysis, accounting, treasury, and international responsibility gained during his 18 years with Amgen.
In his most recent position, as vice president of manufacturing finance, Mr Gustafson was responsible for financial planning and cost accounting for each of Amgen’s worldwide manufacturing sites and the Cost Accounting Group.
Jonathan Lim, president and CEO of Halozyme, said: “We are delighted to welcome an individual with Kurt’s industry experience, stature and expertise as an integral new member of our executive leadership team at Halozyme. Kurt’s knowledge and experience will be of tremendous value as we enter the next phase of our growth.”